Cardiff Oncology, Inc. (CRDF)
1.37
+0.07
(+5.38%)
USD |
NASDAQ |
Sep 18, 16:00
1.37
0.00 (0.00%)
After-Hours: 20:00
Cardiff Oncology Enterprise Value : 59.78M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 59.78M |
| September 17, 2026 | 54.99M |
| September 16, 2026 | 58.41M |
| September 15, 2026 | 57.73M |
| September 14, 2026 | 55.67M |
| September 11, 2026 | 48.82M |
| September 10, 2026 | 48.82M |
| September 09, 2026 | 37.86M |
| September 08, 2026 | 41.29M |
| September 04, 2026 | 40.60M |
| September 03, 2026 | 39.92M |
| September 02, 2026 | 38.55M |
| September 01, 2026 | 36.49M |
| August 31, 2026 | 34.00M |
| August 28, 2026 | 30.33M |
| August 27, 2026 | 33.49M |
| August 26, 2026 | 33.35M |
| August 25, 2026 | 35.81M |
| August 24, 2026 | 34.30M |
| August 21, 2026 | 26.23M |
| August 20, 2026 | 28.18M |
| August 19, 2026 | 27.44M |
| August 18, 2026 | 26.64M |
| August 17, 2026 | 27.88M |
| August 14, 2026 | 31.90M |
| Date | Value |
|---|---|
| August 13, 2026 | 33.34M |
| August 12, 2026 | 33.79M |
| August 11, 2026 | 37.86M |
| August 10, 2026 | 36.49M |
| August 07, 2026 | 33.88M |
| August 06, 2026 | 31.73M |
| August 05, 2026 | 31.36M |
| August 04, 2026 | 29.57M |
| August 03, 2026 | 29.92M |
| July 31, 2026 | 24.53M |
| July 30, 2026 | 24.23M |
| July 29, 2026 | 21.42M |
| July 28, 2026 | 21.97M |
| July 27, 2026 | 23.20M |
| July 24, 2026 | 22.58M |
| July 23, 2026 | 23.35M |
| July 22, 2026 | 24.85M |
| July 21, 2026 | 23.48M |
| July 20, 2026 | 23.38M |
| July 17, 2026 | 26.22M |
| July 16, 2026 | 25.84M |
| July 15, 2026 | 26.86M |
| July 14, 2026 | 55.67M |
| July 13, 2026 | 58.41M |
| July 10, 2026 | 57.04M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.815B |
| Alnylam Pharmaceuticals, Inc. | 31.72B |
| Anika Therapeutics, Inc. | 265.34M |
| Savara, Inc. | 960.37M |
| Vericel Corp. | 1.980B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.232M |
| Revenue (Quarterly) | 0.104M |
| Total Expenses (Quarterly) | 9.336M |
| EPS Diluted (Quarterly) | -0.1351 |
| Gross Profit Margin (Quarterly) | -113.5% |
| Profit Margin (Quarterly) | -8.88K% |
| Earnings Yield | -43.11% |
| Normalized Earnings Yield | -43.10 |